Trials / Completed
CompletedNCT05532735
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Retinal Vein Occlusion
Open-label, Dose Ascending Safety, Tolerability, and Proof of Concept Study to Evaluate the Use of ANXV (Human Recombinant Annexin A5) in the Treatment of Subjects With Recently Diagnosed Retinal Vein Occlusion
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Annexin Pharmaceuticals AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, dose ascending safety, tolerability, and proof of concept study to evaluate the use of ANXV (human recombinant Annexin A5) in the treatment of subjects with recently diagnosed Retinal Vein Occlusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ANXV | ANXV (Human recombinant Annexin A5 protein) |
Timeline
- Start date
- 2022-08-24
- Primary completion
- 2024-07-17
- Completion
- 2024-11-11
- First posted
- 2022-09-08
- Last updated
- 2024-12-11
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05532735. Inclusion in this directory is not an endorsement.